Tower Research Capital (TRC)’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $76.8K | Buy |
3,918
+2,131
| +119% | +$52.1K | ﹤0.01% | 2389 |
|
|
2025
Q4 | $47.9K | Buy |
1,787
+965
| +117% | +$24.9K | ﹤0.01% | 2452 |
|
|
2025
Q3 | $21.9K | Sell |
822
-2,761
| -77% | -$71.3K | ﹤0.01% | 3233 |
|
|
2025
Q2 | $82.3K | Buy |
3,583
+2,596
| +263% | +$64.4K | ﹤0.01% | 2542 |
|
|
2025
Q1 | $28.6K | Sell |
987
-158
| -14% | -$5.05K | ﹤0.01% | 2656 |
|
|
2024
Q4 | $42.5K | Buy |
1,145
+348
| +44% | +$15.9K | ﹤0.01% | 2657 |
|
|
2024
Q3 | $38.7K | Sell |
797
-7,661
| -91% | -$336K | ﹤0.01% | 2869 |
|
|
2024
Q2 | $338K | Buy |
8,458
+7,277
| +616% | +$302K | 0.01% | 1651 |
|
|
2024
Q1 | $51.9K | Sell |
1,181
-10,275
| -90% | -$531K | ﹤0.01% | 2250 |
|
|
2023
Q4 | $709K | Buy |
11,456
+10,291
| +883% | +$541K | 0.01% | 1098 |
|
|
2023
Q3 | $53.6K | Buy |
1,165
+23
| +2% | +$1.25K | ﹤0.01% | 2492 |
|
|
2023
Q2 | $65.6K | Sell |
1,142
-856
| -43% | -$37.9K | ﹤0.01% | 2359 |
|
|
2023
Q1 | $75K | Buy |
1,998
+1,347
| +207% | +$44.2K | ﹤0.01% | 2130 |
|
|
2022
Q4 | $18K | Sell |
651
-4,492
| -87% | -$130K | ﹤0.01% | 3198 |
|
|
2022
Q3 | $144K | Buy |
5,143
+3,044
| +145% | +$99.4K | ﹤0.01% | 2227 |
|
|
2022
Q2 | $73K | Sell |
2,099
-8,184
| -80% | -$292K | ﹤0.01% | 2534 |
|
|
2022
Q1 | $370K | Buy |
10,283
+9,196
| +846% | +$261K | ﹤0.01% | 1330 |
|
|
2021
Q4 | $25K | Sell |
1,087
-3,380
| -76% | -$69.1K | ﹤0.01% | 3409 |
|
|
2021
Q3 | $85K | Buy |
4,467
+2,205
| +97% | +$43.2K | ﹤0.01% | 2523 |
|
|
2021
Q2 | $46K | Sell |
2,262
-48
| -2% | -$904 | ﹤0.01% | 3080 |
|
|
2021
Q1 | $42K | Buy |
2,310
+1,273
| +123% | +$23.7K | ﹤0.01% | 3262 |
|
|
2020
Q4 | $21K | Sell |
1,037
-13,125
| -93% | -$255K | ﹤0.01% | 3828 |
|
|
2020
Q3 | $266K | Buy |
14,162
+10,233
| +260% | +$206K | ﹤0.01% | 2289 |
|
|
2020
Q2 | $88K | Buy |
+3,929
| New | +$72K | ﹤0.01% | 2570 |
|
|
2019
Q2 | – | Sell |
-505
| Closed | -$10K | – | 3625 |
|
|
2019
Q1 | $10K | Buy |
+505
| New | +$11.3K | ﹤0.01% | 2661 |
|
|
2018
Q3 | – | Sell |
-2,642
| Closed | -$40K | – | 3724 |
|
|
2018
Q2 | $40K | Sell |
2,642
-16
| -0.6% | -$280 | ﹤0.01% | 1964 |
|
|
2018
Q1 | $50K | Buy |
+2,658
| New | +$50K | ﹤0.01% | 1671 |
|
|
2017
Q4 | – | Sell |
-7,623
| Closed | -$136K | – | 3472 |
|
|
2017
Q3 | $136K | Buy |
+7,623
| New | +$125K | 0.01% | 1075 |
|
|
2017
Q2 | – | Sell |
-2,558
| Closed | -$37K | – | 2654 |
|
|
2017
Q1 | $37K | Buy |
2,558
+1,102
| +76% | +$17.3K | ﹤0.01% | 890 |
|
|
2016
Q4 | $27K | Buy |
+1,456
| New | +$28.3K | ﹤0.01% | 1867 |
|
|
2016
Q3 | – | Sell |
-1,123
| Closed | -$18K | – | 3578 |
|
|
2016
Q2 | $18K | Buy |
1,123
+323
| +40% | +$4.56K | ﹤0.01% | 2314 |
|
|
2016
Q1 | $10K | Buy |
+800
| New | +$9.43K | ﹤0.01% | 1931 |
|
|
2015
Q3 | – | Sell |
-2,960
| Closed | -$52K | – | 3949 |
|
|
2015
Q2 | $52K | Buy |
+2,960
| New | +$46.1K | ﹤0.01% | 1321 |
|
|
2015
Q1 | – | Sell |
-872
| Closed | -$10K | – | 4371 |
|
|
2014
Q4 | $10K | Sell |
872
-3,888
| -82% | -$42.3K | ﹤0.01% | 2126 |
|
|
2014
Q3 | $55K | Buy |
+4,760
| New | +$49.6K | 0.01% | 1449 |
|
Other funds holding AMPH
VCM
BTW
Tower Research Capital (TRC)'s AMPH Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Amphastar Pharmaceuticals (AMPH) stake by 119% in Q1 2026, buying an estimated $52.1K and bringing the position to 3,918 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2389.
Tower Research Capital (TRC) first reported a position in AMPH in Q3 2014 and has held it in 35 quarters since. The position peaked at $709K in Q4 2023. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.
- Tower Research Capital (TRC) held 3,918 shares of Amphastar Pharmaceuticals worth $76.8K as of Q1 2026.
- Tower Research Capital (TRC) bought 2,131 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $52.1K.
- Amphastar Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2389 holding.
- Tower Research Capital (TRC) first reported a position in Amphastar Pharmaceuticals in Q3 2014 and has held it in 35 quarters since.
- Tower Research Capital (TRC)'s Amphastar Pharmaceuticals position peaked at $709K in Q4 2023.
- 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.